|Articles|September 14, 2021
- Pharmaceutical Executive-09-01-2021
- Volume 41
- Issue 9
Pharmaceutical Executive, September 2021 Issue (PDF)
Click the title above for a link to open the Pharmaceutical Executive September 2021 issue in an interactive PDF format.
Advertisement
Articles in this issue
over 4 years ago
When Innovation Outpaces HTA, Access Struggles to Keep Upover 4 years ago
Doubling Down On Innovation, Recoveryover 4 years ago
Developing a Product Launch Strategy for an Orphan Drugover 4 years ago
Investing for Success: Finding the Right Launch Balanceover 4 years ago
Rethinking Obesity: Wegovyover 4 years ago
Fear Factor: Palforziaover 4 years ago
Formidable Option: Orgovyxover 4 years ago
No Small Feat: Nurtec ODTover 4 years ago
‘Rare’ Reinforcement: Evrysdiover 4 years ago
Serial Problem SolverNewsletter
Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.
Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
Roche Announces Positive Topline Results from Phase II Study for Dual GLP-1/GIP Receptor Agonist
2
Boehringer Ingelheim Enters $1.26 Billion Collaboration and License Agreement with Simcere Pharmaceuticals to Develop Pre-Clinical Bispecific Antibody
3
Pharmaceutical Executive Daily: Roche Reports Positive Phase II Study Results for Dual GLP-1/GIP Receptor Agonist
4
Bringing a Breakthrough Rare Disease Product to Patients: Q&A with Helen Sabzevari
5